Stock Report

Dr. Reddy's Laboratories launches its authorized generic version of VASOSTRICT® Vials in the U.S. Market



Posted On : 2022-02-10 08:13:34( TIMEZONE : IST )

Dr. Reddy's Laboratories launches its authorized generic version of VASOSTRICT® Vials in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") has announced the launch of its authorized generic version of Par Pharmaceutical's VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).

"We are pleased to provide this important authorized generic product to patients, especially in these difficult times of COVID-19," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories Inc.

The VASOSTRICT® brand market had U.S. sales of approximately $878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health*.

Dr. Reddy's Vasopressin Injection, USP, is supplied in a carton of 25 single-dose vials each containing vasopressin 1 mL at 20 units/mL.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4366.50 as compared to the previous close of Rs. 4320.25. The total number of shares traded during the day was 8364 in over 1178 trades.

The stock hit an intraday high of Rs. 4393.55 and intraday low of 4313.30. The net turnover during the day was Rs. 36481191.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY VASOSTRICTVials GenericVersion VasopressinInjection USFDA